Status and phase
Conditions
Treatments
About
This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.
Full description
This study is a Phase 1b, randomized, double-blind, placebo controlled, multi-ascending dose study of repeat doses of PMN310 to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of multiple intravenous infusions of PMN310 in patients with early Alzheimer's disease. This study will evaluate 3 dose levels (350 mg, 700 mg, and 1400 mg are planned). Patients will be randomly assigned 3:1, PMN310: placebo.
Each patient will receive PMN310 or placebo once every 28 days for a total of 12 infusions.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patient and caregiver provide written informed consent.
Ambulatory male or female ≥ 50 years of age with adequate visual and auditory abilities to perform the cognitive and functional assessments in the opinion of the Investigator.
Meets all of the following clinical criteria for mild cognitive impairment (MCI) due to AD or mild AD dementia at Screening:
Body mass index between 18.5 and 35 kg/m2 inclusive.
Patients of childbearing potential must meet the following criteria:
Patients of non-childbearing potential must meet 1 of the following:
Has a reliable caregiver who agrees to accompany the patient at study visits, accurately report patient's status, provide feedback on functional and safety assessments, and ensure compliance to study requirements.
Confirmed to have acceptable venous access for blood collections and IV administration of study drug (i.e., PMN310 or placebo).
Patients taking Food and Drug Administration-approved acetylcholinesterase inhibitors or memantine are allowed as long as the dose has been stable for at least 3 months prior to Screening.
Exclusion criteria
Living in a continuous care or long-term care nursing facility. Patients in outpatient living at home or in an assisted living facility are eligible for the study.
Medical or neurological condition (other than AD; i.e., Parkinson's disease, Huntington's disease, frontal temporal dementia, dementia with Lewy bodies) judged to be contributing to the patient's cognitive impairment.
Laboratory and electrocardiogram (ECG) abnormalities:
In the opinion of the Investigator, any clinically significant current or relevant history of physical or psychiatric illness (including suicidal risk, ideation, behavior, or suicide attempts), any medical disorder that may require treatment or make the patient unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or procedures.
Clinically significant recurrent disease or unstable disease that could affect the action, absorption, or disposition of the investigational product, or could affect clinical or laboratory assessments, such as (but not limited to) the following:
Experienced a significant systemic illness, as judged by the Investigator, within 30 days of the first dose of study drug.
Seizure in the 3 years prior to Screening.
History of a clinically significant medical condition that would interfere with the patient's ability to comply with study instructions, would place the patient at increased risk, or might confound the interpretation of the study results.
History of prior malignancy (except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix).
Brain MRI with evidence of any of the following findings: >4 microhemorrhages; >1 lobar microhemorrhage; area of superficial siderosis; subarachnoid hemorrhage; any other hemorrhage >10 mm; >2 lacunar infarcts or cortical infarct; subjects with severe perivascular spaces or with what matter hyperintensities in a multisport pattern will require PI review prior to inclusion.
History of stroke or transient ischemic attack within 12 months prior to Screening.
Contraindication to PET or brain MRI.
Negative PET scan with any amyloid-targeting ligand within 6 months of Screening or during Screening.
Pregnant or breastfeeding.
History of alcohol abuse and/or other substance abuse within 12 months prior to dosing with study drug.
Positive test for alcohol (using an alcohol breath test) or illicit drugs of abuse at Screening.
Documented history of human immunodeficiency virus antibody.
Coronavirus disease 2019 (COVID-19) infection within 2 weeks of Screening or ongoing symptoms of COVID-19 at Screening.
Currently receiving an anti-amyloid treatment, either marketed (aducanumab, lecanemab, donanemab) or investigational or has received anti amyloid therapy within 9 months prior to Screening. In the case of investigational treatment, those known to have received placebo will not be excluded.
Contraindication to undergoing lumbar puncture (LP) including: sensitivity to local anesthetic, international normalized ratio (INR) > 1.4 or other coagulopathy, platelet cell count of < 120,000/µL, infection at the desired LP site, current use of anti-coagulant medication except for low dose aspirin, degenerative arthritis, spinal scoliosis, back surgery, suspected increased intracranial pressure on history or neurologic exam, non-communicating hydrocephalus or intracranial mass, or prior history of spinal mass or trauma and/or other known clinically significant spinal abnormalities.
Donated blood or blood products (e.g., plasma, platelets) within 56 days prior to first dose of study drug.
Received an investigational active agent (e.g., not placebo) within the last 30 days or 5 half-lives, whichever is longer (if known).
Known history of severe allergic reaction or hypersensitivity to any components of the PMN310 infusion.
Primary purpose
Allocation
Interventional model
Masking
128 participants in 3 patient groups
Loading...
Central trial contact
Wendy Luca
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal